Clinical Trial Update: Corneal Thinning During Topical Bevacizumab Therapy [NA]

View source ↗

Summary

A clinical trial evaluating topical bevacizumab for corneal neovascularization has been withdrawn, with concerns about corneal thinning observed during therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Neovascularization

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Yonsei University | Conditions: Corneal Neovascularization | NA | Status: WITHDRAWN